CONTINEUM THERAPEUTICS INC-A (CTNM)
US21217B1008 - Common Stock
Overall CTNM gets a fundamental rating of 4 out of 10. We evaluated CTNM against 196 industry peers in the Pharmaceuticals industry. CTNM is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CTNM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CTNM was profitable.
1.2 Ratios
With an excellent Return On Assets value of 10.26%, CTNM belongs to the best of the industry, outperforming 92.27% of the companies in the same industry.
Looking at the Return On Equity, with a value of 10.45%, CTNM belongs to the top of the industry, outperforming 88.66% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.84%, CTNM belongs to the top of the industry, outperforming 85.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.26% | ||
| ROE | 10.45% | ||
| ROIC | 5.84% |
ROA(3y)-23.87%
ROA(5y)N/A
ROE(3y)-30.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 45.44%, CTNM belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
Looking at the Operating Margin, with a value of 32.15%, CTNM belongs to the top of the industry, outperforming 95.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.15% | ||
| PM (TTM) | 45.44% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CTNM is destroying value.
Compared to 1 year ago, CTNM has about the same amount of shares outstanding.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 65.43 indicates that CTNM is not in any danger for bankruptcy at the moment.
CTNM has a Altman-Z score of 65.43. This is amongst the best in the industry. CTNM outperforms 97.42% of its industry peers.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 65.43 |
ROIC/WACC0.64
WACC9.17%
2.3 Liquidity
A Current Ratio of 58.92 indicates that CTNM has no problem at all paying its short term obligations.
With an excellent Current ratio value of 58.92, CTNM belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
CTNM has a Quick Ratio of 58.92. This indicates that CTNM is financially healthy and has no problem in meeting its short term obligations.
CTNM has a better Quick ratio (58.92) than 99.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 58.92 | ||
| Quick Ratio | 58.92 |
3. Growth
3.1 Past
CTNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 193.68%, which is quite impressive.
EPS 1Y (TTM)193.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CTNM will show a very negative growth in Earnings Per Share. The EPS will decrease by -74.37% on average per year.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y-314.36%
EPS Next 2Y-96.37%
EPS Next 3Y-74.37%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-60.88%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.09, the valuation of CTNM can be described as rather expensive.
Based on the Price/Earnings ratio, CTNM is valued cheaper than 86.08% of the companies in the same industry.
When comparing the Price/Earnings ratio of CTNM to the average of the S&P500 Index (31.46), we can say CTNM is valued slightly cheaper.
The Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.09 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CTNM is valued cheaper than 97.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.27 |
4.3 Compensation for Growth
CTNM's earnings are expected to decrease with -74.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.37%
EPS Next 3Y-74.37%
5. Dividend
5.1 Amount
No dividends for CTNM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CONTINEUM THERAPEUTICS INC-A
NASDAQ:CTNM (10/22/2024, 4:30:01 PM)
After market: 16.28 0 (0%)16.28
+0.21 (+1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap418.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.09 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.26% | ||
| ROE | 10.45% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 32.15% | ||
| PM (TTM) | 45.44% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 58.92 | ||
| Quick Ratio | 58.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)193.68%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-314.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y